AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21516735 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam (8 or 12 mg/daily) for 15 days in addition to standard treatment
Number of subjects: 85
Study 21516735 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 21516735 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam
Number of subjects: 85
Study 17122979 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed training on 3 consecutive days (group A)
Number of subjects: 20
Study 17122979 — intervention group
Group type: COMPARATOR
Intervention: Distributed training within 1 day (group B)
Number of subjects: 20
Study 16168782 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (70 mg) weekly for 12 months
Number of subjects: 1665
Study 11935032 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14 C(‐260)T gene polymorphism
Number of subjects: 338
Study 11935032 — intervention group
Group type: EXPERIMENTAL
Intervention: CD18 codon 441 gene polymorphism
Number of subjects: 338
Study 11935032 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant or recessive model
Number of subjects: 338
Study 11935032 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis restricted to thromboembolic events
Number of subjects: 338
Study 9950944 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training for 6 weeks
Number of subjects: 9
Study 9950944 — intervention group
Group type: COMPARATOR
Intervention: Concentric training for 6 weeks
Number of subjects: 9
Study 7646769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal mononuclear cell immunization before conception
Number of subjects: 200
Study 7646769 — intervention group
Group type: COMPARATOR
Intervention: Paternal mononuclear cell immunization after conception
Number of subjects: 200
Study 2486813 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential phospholipid choline capsules (EPLC) for a six weeks period
Number of subjects: 46
Study 2486813 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B complex capsules
Number of subjects: 46
Study 1007830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg perorally
Number of subjects: 14
Study 1007830 — intervention group
Group type: COMPARATOR
Intervention: Atropine sulphate infusion
Number of subjects: 14
Study 30762318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 40
Study 30762318 — intervention group
Group type: COMPARATOR
Intervention: Phantom Exercises (PE)
Number of subjects: 40
Study 28790141 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (40/5.7 mg/kg per day)
Number of subjects: 319
Study 28790141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 25872631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing high-molecular-weight component of cranberry (3 mg/ml)
Number of subjects: 20
Study 25872631 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (control)
Number of subjects: 20
Study 23409801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training group (5 sets at 5-8 RM half-squats with sprints between each set)
Number of subjects: 26
Study 23409801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 23409801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training group
Number of subjects: 26
Study 21641580 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet guided self-help treatment programme based on CBT for 6 months with a 6-month follow-up
Number of subjects: 74
Study 21641580 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control for 6 months before intervention
Number of subjects: 74
Study 19799568 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in non-VA EDs
Number of subjects: 959
Study 19799568 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in VA EDs
Number of subjects: 959
Study 17038141 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg daily in three divided doses for 3 days before cardioversion and 1 week after
Number of subjects: 23
Study 17038141 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg daily
Number of subjects: 23
Study 17038141 — intervention group
Group type: COMPARATOR
Intervention: Usual medication (Control)
Number of subjects: 23
Study 14764444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecanoic acid (C12)
Number of subjects: 0
Study 14764444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decanoic acid (C10)
Number of subjects: 0
Study 14764444 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 11043499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A plus prednisone
Number of subjects: 18
Study 11043499 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone alone
Number of subjects: 18
Study 9294380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 107
Study 9294380 — intervention group
Group type: COMPARATOR
Intervention: Systemic behavior family therapy (SBFT)
Number of subjects: 107
Study 9294380 — intervention group
Group type: COMPARATOR
Intervention: Individual nondirective supportive therapy (NST)
Number of subjects: 107
Study 8095622 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine (n = 738)
Number of subjects: 1548
Study 8095622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 810)
Number of subjects: 1548
Study 3527555 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 500 mg acetylsalicylic acid and 3 X 75 mg dipyridamole per day (treated group)
Number of subjects: 0
Study 3527555 — intervention group
Group type: COMPARATOR
Intervention: Control group without medication
Number of subjects: 0
Study 29566543 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot-based gel (BG) supplementation
Number of subjects: 12
Study 29566543 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted gel (PLA)
Number of subjects: 12
Study 27472567 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish (four applications with one‐week interval)
Number of subjects: 51
Study 27472567 — intervention group
Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 51
Study 25195352 — intervention group
Group type: EXPERIMENTAL
Intervention: P. oleracea seeds (500 mg) taken two times a day for one month
Number of subjects: 100
Study 25195352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose) capsules taken two times a day for one month
Number of subjects: 100
Study 22388528 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 144
Study 22388528 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 144
Study 20636946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's perception of maternal aggression
Number of subjects: 99
Study 18676516 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game intervention addressing cancer treatment and care
Number of subjects: 375
Study 18676516 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 375
Study 15995847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks, then the same dose for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks)
Number of subjects: 28
Study 15995847 — intervention group
Group type: COMPARATOR
Intervention: Placebo according to the same schedule as fusidin
Number of subjects: 28
Study 15995847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fusidate (fusidin)
Number of subjects: 28
Study 15995847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12795777 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of 500 mg clarithromycin tablet
Number of subjects: 24
Study 12795777 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of 500 mg clarithromycin tablet
Number of subjects: 24
Study 10332969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered joint counts (JC)
Number of subjects: 0
Study 10332969 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint scores (JS)
Number of subjects: 0
Study 10332969 — intervention group
Group type: COMPARATOR
Intervention: Trained assessor joint counts (JC)
Number of subjects: 0
Study 9073058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index derived from 384 randomly selected patients
Number of subjects: 495
Study 9073058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index tested in 111 other patients
Number of subjects: 495
Study 1854609 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected cancers
Number of subjects: 840
Study 1854609 — intervention group
Group type: COMPARATOR
Intervention: Nonattenders and control group cancers
Number of subjects: 840
Study 1854609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers detected at prevalence and incidence screens
Number of subjects: 840
Study 1854609 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological characteristics of cancers
Number of subjects: 840
Study 6135442 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training programme (improves maximal oxygen consumption)
Number of subjects: 27
Study 6135442 — intervention group
Group type: COMPARATOR
Intervention: Physical training programme (does not change oxygen consumption)
Number of subjects: 27
Study 30178727 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling (PE)
Number of subjects: 961
Study 30178727 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated feedback letters (CO)
Number of subjects: 961
Study 30178727 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 961
Study 30097716 — intervention group
Group type: EXPERIMENTAL
Intervention: Galletti-Contrino manoeuvre
Number of subjects: 204
Study 30097716 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont-Toupet manoeuvre
Number of subjects: 204
Study 30097716 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-overweight subjects)
Number of subjects: 204
Study 26728978 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g RUTF/day
Number of subjects: 65
Study 26728978 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hospital diet alone)
Number of subjects: 65
Study 24718270 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated PDS Plus sutures (PDS Plus)
Number of subjects: 1224
Study 24718270 — intervention group
Group type: COMPARATOR
Intervention: Uncoated PDS II sutures (PDS II)
Number of subjects: 1224
Study 22111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan and amlodipine (combination therapy)
Number of subjects: 0
Study 19434801 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered vegetable intake
Number of subjects: 0
Study 19434801 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 17728218 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year screening interval (Gothenburg)
Number of subjects: 17503
Study 17728218 — intervention group
Group type: COMPARATOR
Intervention: 4-year screening interval (Rotterdam)
Number of subjects: 17503
Study 15277162 — intervention group
Group type: COMPARATOR
Intervention: Basic diet (BD) with low calcium (224 mg Ca/d)
Number of subjects: 14
Study 15277162 — intervention group
Group type: EXPERIMENTAL
Intervention: BD with milk (826 mg Ca/d)
Number of subjects: 14
Study 15277162 — intervention group
Group type: EXPERIMENTAL
Intervention: BD with calcium lactate (802 mg Ca/d)
Number of subjects: 14
Study 15277162 — intervention group
Group type: EXPERIMENTAL
Intervention: BD with milk mineral isolate (801 mg Ca/d)
Number of subjects: 14
Study 11673021 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (2.5, 5 or 7.5 mg/day) plus levetiracetam 1000 mg bid
Number of subjects: 42
Study 11673021 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (2.5, 5 or 7.5 mg/day) plus placebo
Number of subjects: 42
Study 11673021 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 42
Study 9305422 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0
Study 9305422 — intervention group
Group type: COMPARATOR
Intervention: Vodka
Number of subjects: 0
Study 7932170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) 100 mg administered intravenously (i.v.)
Number of subjects: 9
Study 7932170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) 100 mg administered orally (p.o.)
Number of subjects: 9
Study 7932170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) administered by both routes
Number of subjects: 9
Study 7932170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) administered intravenously (i.v.)
Number of subjects: 9
Study 3501375 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous prophylaxis with trimethoprim-sulfamethoxazole (5-25 mg/kg/day/p.o.)
Number of subjects: 0
Study 3501375 — intervention group
Group type: COMPARATOR
Intervention: Intermittent prophylaxis with trimethoprim-sulfamethoxazole (3 days/week, 5-25 mg/kg/day/p.o.)
Number of subjects: 0
Study 31929340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for melanoma in situ (MIS) before ACA
Number of subjects: 24678
Study 31929340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for melanoma in situ (MIS) after ACA
Number of subjects: 24678
Study 31929340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for rare cutaneous tumors (RCT) after ACA
Number of subjects: 24678
Study 31929340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for melanoma in situ (MIS) after AUC
Number of subjects: 24678
Study 31929340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for rare cutaneous tumors (RCT) after AUC
Number of subjects: 24678
Study 29643070 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine therapy
Number of subjects: 870
Study 29643070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 27083914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sojourners (high school exchange students)
Number of subjects: 457
Study 27083914 — intervention group
Group type: COMPARATOR
Intervention: Control group (German adolescents)
Number of subjects: 457
Study 24659891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy (iron depletion)
Number of subjects: 38
Study 24659891 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes alone
Number of subjects: 38
Study 22877848 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m² on days 1-5 of every 28 days for up to six cycles)
Number of subjects: 342
Study 22877848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (34.0 Gy administered in 3.4 Gy fractions over 2 weeks)
Number of subjects: 342
Study 22877848 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m²)
Number of subjects: 342
Study 22877848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 342
Study 22877848 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide with MGMT promoter methylation
Number of subjects: 342
Study 22877848 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 342
Study 20843910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontario OH patients
Number of subjects: 300
Study 20843910 — intervention group
Group type: COMPARATOR
Intervention: OBRI patients
Number of subjects: 300
Study 18852623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (N=8)
Number of subjects: 17
Study 18852623 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (N=9)
Number of subjects: 17
Study 16091766 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral 800 IU (727 mg) of alpha‐tocopherol and 500 mg of vitamin C (n = 24)
Number of subjects: 48
Study 16091766 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 24)
Number of subjects: 48
Study 12204662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response assessment using WHO or RECIST criteria
Number of subjects: 0
Study 12204662 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of biological response assessment
Number of subjects: 0
Study 10519481 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride ophthalmic solution 0.5%
Number of subjects: 11
Study 10519481 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 11
Study 7735340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat counseling (20 g/day fat reduction)
Number of subjects: 122
Study 7735340 — intervention group
Group type: COMPARATOR
Intervention: Calorie counseling (1000 to 1200 kcal/day)
Number of subjects: 122
Study 2404555 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and combination chemotherapy (cyclophosphamide, Adriamycin, methotrexate, procarbazine)
Number of subjects: 111
Study 2404555 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 111
Study 7369096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (500 units by intravenous infusion every 12 hours)
Number of subjects: 0
Study 7369096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully anticoagulated group (heparin by intravenous infusion and warfarin sodium to maintain a whole blood clotting time of 30 to 90 minutes and a prothrombin index of 10% to 35%)
Number of subjects: 0
Study 7369096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 0
Study 7369096 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with cardiac failure)
Number of subjects: 0
Study 7369096 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without cardiac failure)
Number of subjects: 0
Study 31202468 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (30 mg/kg per day divided into two equal doses)
Number of subjects: 88
Study 31202468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 31202468 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 88
Study 31202468 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (continuation in extension study)
Number of subjects: 88
Study 31202468 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Deferiprone (in extension study)
Number of subjects: 88
Study 31202468 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone–deferiprone group
Number of subjects: 88
Study 31202468 — intervention group
Group type: COMPARATOR
Intervention: Placebo–deferiprone group
Number of subjects: 88
Study 28124502 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Bias Internalization (WBI)
Number of subjects: 178
Study 28124502 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBI (vs. low WBI)
Number of subjects: 178
Study 25479835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)
Number of subjects: 0
Study 25479835 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4,000 IU/day)
Number of subjects: 0
Study 25479835 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD)
Number of subjects: 0
Study 23898612 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GSVL)
Number of subjects: 40
Study 23898612 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 40
Study 20963404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (500 mg with 200 mg ritonavir, steady state)
Number of subjects: 29
Study 20963404 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir (single dose)
Number of subjects: 29
Study 19415409 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran
Number of subjects: 13
Study 19415409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat powder
Number of subjects: 13
Study 19415409 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (mixture of fibres)
Number of subjects: 13
Study 19415409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-rich meals (general)
Number of subjects: 13
Study 19415409 — intervention group
Group type: COMPARATOR
Intervention: Control meal (no added fibre)
Number of subjects: 13
Study 15808927 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized test with 250 ml fluid meal (250 kcal: 9.4 g protein, 34.4 g carbohydrates, and 8.3 g fat) at admission
Number of subjects: 20
Study 15808927 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized test with 250 ml fluid meal after partial weight gain (2.8 +/- 0.1 kg; BMI 16.1 +/- 0.3 kg/m2)
Number of subjects: 20
Study 15808927 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized test with 250 ml fluid meal at discharge (weight gain: 7.6 +/- 0.5 kg; BMI 17.9 +/- 0.4 kg/m2)
Number of subjects: 20
Study 15808927 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 6; BMI 21.1 +/- 0.7 kg/m2)
Number of subjects: 20
Study 12429544 — intervention group
Group type: EXPERIMENTAL
Intervention: Southampton examination schedule
Number of subjects: 97
Study 10487487 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with CAD
Number of subjects: 55
Study 10487487 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study 8695462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative visits by theatre nurses
Number of subjects: 2
Study 8695462 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative visits
Number of subjects: 2
Study 1960553 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐3 (rhIL‐3) administered by a single intravenous (IV) bolus injection followed by subcutaneous (SC) injections once daily from day 2 to 15 at doses of 60, 125, 250, and 500 micrograms/m2
Number of subjects: 30
Study 1960553 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐3 (rhIL‐3)
Number of subjects: 30
Study 7200788 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 0
Study 7200788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0